Saliva and plasma levels of carbamazepine have a poor correlation: A pilot study;Relación entre niveles de carbamazepina en saliva y plasma: Estudio piloto

Revista Medica de Chile

Volumn 135, Issue 3, 2007, Pages 335-340

  Mennickent C, Sigrid ^a   Vega H, Mario ^a   Godoy M, Carmen Gloria ^a   León H, M Doris ^b  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b Hospital Las Higueras   (Chile)

Author keywords

Carbamazepine; Epilepsy; Saliva

Indexed keywords

EID: 34247568358     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. GARNETT W. Antiepileptic drug treatment: outcomes and adherence. Pharmacotherapy 2000; 20 (8Pt2): 191S-199S.
2. a Ed., Mc Graw-Hill, México, 2003.
3. LIU H, DELGADO M, FORMAN LJ, EGGERS CM, MONTOYA JL. Simultaneous determination of carbamazepine, phenytoin, phenobarbital, primidone and their principal metabolites by high-performance liquid chromatography with photodiodearray detection. J Chromatography 1993; 616: 105-15.
4. a Ed, Lippincott-Raeven, Philadelphia, 1998.
5. RYAN N, BATHARA V, PEREL J. Mood stabilizers in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38: 529-36.
6. PAGE C. Farmacología Integrada, Harcourt, Madrid, 1999.
7. Drug Evaluations Annual 1995, American Medical Association, 1995.
8. a Ed., American Hospital Formulary Service, USA, 2005.
9. a Ed., Mosby-Year book, Inc., St Louis, USA, 1998.
10. BHATTI M, HANSON G, SCHULTZ L. Simultaneous determination of phenytoin, carbamazepine and 10,11-carbamazepine epoxide in human plasma by high performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal 1998; 16: 1233-40.
11. GHOLAMI K, FARAHANI FB, ZARGHI A. Simultaneous determination of carbamazepine and its major metabolite in serum. Pharm Pharmacol Comm 1998; 4: 197-9.
12. OLANO I, VÁSQUEZ M, FAGIOLINO P. Chronopharmacokinetics of carbamazepine and its metabolite 10,11-epoxide. J Pharm Clin 1998; 17: 153-6.
13. FEREY K. Simultaneous determination of carbamazepine and epoxy-carbamazepine in plasma by HPLC. J Pharm Clin 1997; 16: 136-40.
14. FOWLER J, RYAN M, KASARKIS E. Phenytoin monitoring of patients in a long-term care facility. Hospital Pharmacy 1998; 33: 1097-101.
15. JIMÉNEZ M, DURÁN J, ABADIN J. Factors affecting the free plasma fraction of phenyotin in patients with epilepsy. Clin Drug Invest 1998; 15: 153-7.
16. PICHINI S, ALTTERL I, ZUCCARO P, PACIFICI R. Drug monitoring in nonconventional biological fluids and matrices. Clin Pharmacokinet 1996; 30: 211-28.
17. MENNICKENT S, VEGA M, GODOY CG. Development and validation of a method using instrumental planar chromatography for quantitative analysis of carbamazepine in saliva. J Chil Chem Soc 2003; 48: 71-3.
18. RYLANCE G, MOLRELAND T. Saliva carbamazepine and phenytoin level monitoring. Arch Dis Child 1981; 56: 637-52.
19. TOMLIN PI, MCKINLAY I, SMITH I. A study on carbamazepine levels, including estimation of 10-11 epoxy-carbamazepine and levels in free plasma and saliva. Develop Med Child Neurol 1986; 28: 713-8.
20. COOK CE, AMERSON E, POOLE K, LESSER P, O'TUAMA L. Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioinmunoassay. Clin Pharmacol & Ther 1975; 18: 742-5.
21. STASS H, DALHOFF A, KUBITZA D, SCHUHLY V. Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, adminitered to healthy subjects. Antimicrob Agents Chemoter 1998; 42: 2060-5.
22. ZHAI S, WEI X, PARKER B, KUNZE K, VESTAL R. Relation between plasma and saliva concentrations of enoxacin, ciprofloxacin, and teophylline. Ther Drug Monit 1996; 18: 666-71.
23. OHKUBO T, SUNO M, KUDO M, UNO T, SUGAWARA K. Column-switching high-performance liquid chromatography of ofloxacin in human saliva and correlation of ofloxacin level in saliva and serum. Ther Dug Monit 1996; 18: 598-603.
24. NAKASHIMA M, VEMATSU T, KOSUGE K, OKUYAMA Y, MORINO A, OZAKI M ET AL. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J Clin Pharmacol 1994; 34: 930-7.
25. ORTELLI D, RUDAZ S, CHEVALLEY A-F, MINO A, DEGLON J-J, BALANT L ET AL. Enantioselective análisis of methadone in saliva by liquid chromatographymass spectrometry. J Chromatography A 2000; 871: 163-72.
26. GARCÍA-HERMOSO D, DROMER F, IMPROVISI L, PROVOST F, DUPONT B. Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob Agents Chemother 1995; 39: 656-60.
27. CODD JE, DESAY PB. Formulation, development and in vivo evaluation of a novel bioadhesive lozenge containing a synergistic combination of antifungal agents. Int J Pharm 1998; 173: 13-24.
28. LI S, MY HU FQ. Determination of tinidazole (TNZ) in saliva by HPLC after administration. Chin J Pharm Anal 1997; 17: 307-9.
29. PRESS J, BERKOVITCH M, LAXER R, GIESBRECHT E, SILVERMAN E, KLEIN K ET AL. Evaluation of therapeutic drug monitoring of methotrexate in saliva of children with rheumatic diseases. Ther Drug Monit 1995; 17: 247-50.